Evidence map›Paper›PMID 39072291›Full record

ArticleMolecular therapy. Oncology2024

Comprehensive machine learning-based integration develops a novel prognostic model for glioblastoma.

Qian Jiang, Xiawei Yang, Teng Deng, Jun Yan, Fangzhou Guo, Ligen Mo, Sanqi An, Qianrong Huang

Abstract read
In one paragraph

Article in Molecular therapy. Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Artificial Intelligence-Driven Multi-Omics Approaches in Glioblastoma.International journal of molecular sciences · 2025
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Qian JiangDepartment of Neurosurgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.
Xiawei YangTransplant Medical Center, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Teng DengDepartment of Neurosurgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.
Jun YanDepartment of Neurosurgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.
Fangzhou GuoDepartment of Neurosurgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.
Ligen MoDepartment of Neurosurgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.
Sanqi AnBiosafety Level-3 Laboratory, Life Sciences Institute & Guangxi Collaborative Innovation Center for Biomedicine, Guangxi Medical University, Nanning, Guangxi, China.
Qianrong HuangDepartment of Neurosurgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, we developed a new prognostic model for glioblastoma (GBM) based on an integrated machine learning algorithm. We used univariate Cox regression analysis to identify prognostic genes by combining six GBM cohorts. Based on the prognostic genes, 10 machine learning algorithms were integrated into 117 algorithm combinations, and the artificial intelligence prognostic signature (AIPS) with the greatest average C-index was chosen. The AIPS was compared with 10 previously published models by univariate Cox analysis and the C-index. We compared the differences in prognosis, tumor immune microenvironment (TIME), and immunotherapy sensitivity between the high and low AIPS score groups. The AIPS based on the random survival forest algorithm with the highest average C-index (0.868) was selected. Compared with the previous 10 prognostic models, our AIPS has the highest C-index. The AIPS was closely linked to the clinical features of GBM. We discovered that patients in the low score group had improved prognoses, a more active TIME, and were more sensitive to immunotherapy. Finally, we verified the expression of several key genes by western blotting and immunohistochemistry. We identified an ideal prognostic signature for GBM, which might provide new insights into stratified treatment approaches for GBM patients.

Indexed as

Glioblastomaimmunotherapy.machine learningprognostic signaturetumor immune microenvironment

Identifiers

PMID39072291
PMCPMC11278295

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.